PRTK - Paratek Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Paratek Pharmaceuticals, Inc.

75 Park Plaza
4th Floor
Boston, MA 02116
United States

Full-time employees101

Key executives

NameTitlePayExercisedYear born
Mr. Michael F. BighamChairman & CEO746.67k424.4k1958
Dr. Evan LohPres, Chief Medical Officer, COO & Director703.39k720.47k1959
Mr. Douglas W. PagánChief Financial Officer514.38kN/A1972
Mr. William M. HaskelSr. VP, Gen. Counsel & Corp. Sec.511.13kN/A1962
Mr. Adam WoodrowChief Commercial Officer & VP503.17kN/A1967
Amounts are as of 31 December 2017, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Corporate governance

Paratek Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 March 2019 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder rights: 6; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.